| 0.864 0.034 (4.03%) | 06-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.28 | 1-year : | 1.51 |
| Resists | First : | 1.1 | Second : | 1.29 |
| Pivot price | 0.85  |
|||
| Supports | First : | 0.77 | Second : | 0.64 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 0.88 |
| MA(100) : | 0.91 |
MA(250) : | 3.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.1 |
D(3) : | 21.9 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 13.07 | Low : | 0.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZYBT ] has closed below upper band by 40.5%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.86 - 0.87 | 0.87 - 0.87 |
| Low: | 0.82 - 0.83 | 0.83 - 0.83 |
| Close: | 0.86 - 0.86 | 0.86 - 0.87 |
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Thu, 04 Jun 2026
Zhengye Biotechnology receives Nasdaq bid price deficiency notice - Investing.com
Thu, 04 Jun 2026
Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - Yahoo Finance
Thu, 04 Jun 2026
Zhengye Biotech has 6 months to lift stock back above $1 - Stock Titan
Mon, 06 Apr 2026
Zhengye's new share classes give some holders 20 votes each - Stock Titan
Mon, 06 Apr 2026
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure - Yahoo Finance
Tue, 10 Feb 2026
Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 47 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 51 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.91 |
| Profit Margin | -60 % |
| Operating Margin | -77.1 % |
| Return on Assets (ttm) | -9.5 % |
| Return on Equity (ttm) | -25.2 % |
| Qtrly Rev. Growth | -41 % |
| Gross Profit (p.s.) | 0.5 |
| Sales Per Share | 2.45 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 40 (M) |
| PE Ratio | -3.93 |
| PEG Ratio | 0 |
| Price to Book value | 0.94 |
| Price to Sales | 0.35 |
| Price to Cash Flow | 3.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|